HII to Expand Shipboard and Shore-Based Training Support for the U.S. Navy and Coalition Forces
Under the five-year task order, HII will provide engineering support for every aspect of training systems under the U.S. Naval Surface Warfare Center Dahlgren Division, Dam Neck Activity (NSWCDD DNA), including associated hardware, software, subsystems and elements. Tasks will range from integrated training system hardware and software installation, system certification and testing to troubleshooting, repair and lifecycle sustainment.
'Providing full-cycle support for U.S. Navy, joint, coalition and Department of Defense training systems requires a seamless, well-orchestrated approach and close collaboration with the Navy customer to make sure we're providing the best quality service possible,' said Michael Lempke, president of Mission Technologies' Global Security group. 'We look forward to expanding our relationship with NSWCDD DNA and ensuring our military fleets remain mission-ready through warfare systems superiority.'
HII supports the U.S. naval fleet across various bases and operational theaters worldwide.
A photo accompanying this release is available at: http://hii.com/news/hii-to-expand-shipboard-and-shore-based-training-support-for-the-u-s-navy-and-coalition-forces/.
The company was awarded this task order under the SeaPort Next Generation multiple award contract indefinite delivery/indefinite quantity vehicle. Work will be performed at multiple locations in the U.S. and overseas.
About HII
HII is a global, all-domain defense provider. HII's mission is to deliver the world's most powerful ships and all-domain solutions in service of the nation, creating the advantage for our customers to protect peace and freedom around the world.
As the nation's largest military shipbuilder, and with a more than 135-year history of advancing U.S. national security, HII delivers critical capabilities extending from ships to unmanned systems, cyber, ISR, AI/ML and synthetic training. Headquartered in Virginia, HII's workforce is 44,000 strong. For more information, visit:
HII on the web: https://www.HII.com/
HII on Facebook: https://www.facebook.com/TeamHII
HII on X: https://www.twitter.com/WeAreHII
HII on Instagram: https://www.instagram.com/WeAreHII
Contact:
Greg McCarthy(202) 264-7126gregory.j.mccarthy@hii-co.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fbca9a37-0f5a-4757-a5fb-25a728e0012a
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
TD Cowen Reiterates Buy Rating on Molina Healthcare (MOH) Stock
Molina Healthcare, Inc. (NYSE:MOH) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On July 28, Ryan Langston, an analyst from TD Cowen, reiterated a 'Buy' rating on the company's stock, and the associated price target was lowered to $203.00. The analyst noted that Molina Healthcare, Inc. (NYSE:MOH) continues to effectively manage the medical costs in the challenging environment, mainly in Medicaid, where it is witnessing pressures in behavioral, pharmacy, and inpatient/outpatient care. A doctor in scrubs shaking hands with a patient, representing the healthcare services provided to individuals and families. Molina Healthcare, Inc. (NYSE:MOH) continues to actively work with state partners in order to restore Medicaid rates to appropriate levels. It has considered increased cost trends in the Medicare and Marketplace bids for 2026. Despite challenges, Molina Healthcare, Inc. (NYSE:MOH)'s strategic efforts and adjustments in rate filings reflect growth potential, justifying the analyst's rating. For FY 2025, the Premium revenue is expected to be ~$42 billion, reflecting an increase of ~9% from FY 2024. Molina Healthcare, Inc. (NYSE:MOH) expects its FY 2025 GAAP earnings to be no less than $16.90 per diluted share. Oakmark Funds, advised by Harris Associates, released its Q2 2025 investor letter. Here is what the fund said: 'Molina Healthcare, Inc. (NYSE:MOH) is a leading managed care company. The company is the fourth largest player in managed Medicaid and has consistently delivered industry-leading margins historically. In our view, this is thanks to Molina Healthcare's exceptional management team and culture of operational excellence. Moreover, we think Molina Healthcare has a long runway for growth given its small scale relative to peers and untapped opportunities in their Medicare and Marketplace business segments. Recently, the Medicaid industry has come under substantial pressure due to a challenging redetermination cycle and additional headwinds from legislation under the current administration. This provided the opportunity to, in our view, purchase shares in a best-in-class managed care company at depressed valuation on trough earnings.' While we acknowledge the potential of MOH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Earnings To Watch: Home Depot (HD) Reports Q2 Results Tomorrow
Home improvement retail giant Home Depot (NYSE:HD) will be announcing earnings results this Tuesday before the bell. Here's what to expect. Home Depot beat analysts' revenue expectations by 1.6% last quarter, reporting revenues of $39.86 billion, up 9.4% year on year. It was a slower quarter for the company, with a miss of analysts' EBITDA estimates and gross margin in line with analysts' estimates. Is Home Depot a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Home Depot's revenue to grow 4.9% year on year to $45.27 billion, improving from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $4.69 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Home Depot has missed Wall Street's revenue estimates twice over the last two years. Looking at Home Depot's peers in the home furnishing and improvement retail segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Floor And Decor delivered year-on-year revenue growth of 7.1%, meeting analysts' expectations, and Arhaus reported revenues up 15.7%, topping estimates by 7.4%. Floor And Decor traded up 2.2% following the results while Arhaus was also up 13.5%. Read our full analysis of Floor And Decor's results here and Arhaus's results here. There has been positive sentiment among investors in the home furnishing and improvement retail segment, with share prices up 5.8% on average over the last month. Home Depot is up 9.5% during the same time and is heading into earnings with an average analyst price target of $423.91 (compared to the current share price of $398.50). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Arvinas, Pfizer's Vepdegestrant NDA Accepted by FDA for Breast Cancer Treatment
Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in collaboration with Pfizer Inc. (NYSE:PFE), announced that the US FDA accepted its New Drug Application/NDA for vepdegestrant. The drug is intended to treat patients with estrogen receptor-positive/ER+, human epidermal growth factor receptor 2-negative/HER2-, ESR1-mutated advanced or metastatic breast cancer who have already received endocrine-based therapy. The FDA has set a Prescription Drug User Fee Act/PDUFA action date of June 5, 2026. The NDA is based on data from the Phase 3 VERITAC-2 clinical trial, which showed a statistically significant and clinically meaningful improvement in median progression-free survival for vepdegestrant compared to fulvestrant. The trial enrolled 624 patients at 213 sites across 25 countries, with 270 of these patients having the ESR1 mutation. A biopharma executive in a meeting room discussing the clinical-stage of a new therapy. The results from this trial were recently presented at the American Society of Clinical Oncology/ASCO 2025 Annual Meeting and published in The New England Journal of Medicine. Vepdegestrant is an investigational oral drug that functions as a PROteolysis TArgeting Chimera/PROTAC estrogen receptor degrader. This marks the first time a PROTAC has demonstrated a clinical benefit in breast cancer patients. Arvinas Inc. (NASDAQ:ARVN) is a clinical-stage biotechnology company that engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the US and internationally. While we acknowledge the potential of ARVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
